News Release

6% of under-18s at risk of cognitive decline and more due to anticholinergic medications

Peer-Reviewed Publication


6% of Under-18s Are at Risk of Cognitive Decline and More Due to Anticholinergic Medications

image: Proportion of anticholinergic burden measured through the Anticholinergic Cognitive Burden (ACB) scale (2016), by sex and age. view more 

Credit: Reinold et al, 2021, <em>PLOS ONE</em> (CC-BY 4.0)

In the German population, a surprisingly high 6% of under-18s are at risk of cognitive decline, falls and more from the cumulative effect of anticholinergic medications such as antihistamines and antidepressants.


Article Title: Anticholinergic burden: First comprehensive analysis using claims data shows large variation by age and sex

Funding: The authors received no external funding for this work.

Competing Interests: UH, OR, MB and JR are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology - BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities. The design and conduct of these studies as well as the interpretation and publication are not influenced by the pharmaceutical industry. The study presented was not funded by the pharmaceutical industry. The authors have no relevant financial or non-financial interests to disclose. Moreover, this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Article URL:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.